background
respiratori
syncyti
viru
rsv
recogn
seriou
pathogen
peopl
chronic
cardiopulmonari
condit
immunoprophylaxi
might
consid
adult
highrisk
frequent
sever
rsv
infect
thu
studi
incid
rsvrelat
medic
attend
acut
respiratori
ill
mari
adult
sever
chronic
obstruct
pulmonari
diseas
copd
andor
congest
heart
failur
chf
method
subject
year
age
gold
class
iiiiv
copd
andor
american
heart
associ
class
iiiiv
chf
exposur
children
per
month
recruit
subject
evalu
year
rsvassoci
mari
defin
polymeras
chain
reaction
pcr
andor
serorespons
result
four
hundr
fortyf
subject
enrol
octob
may
overal
rsv
infect
document
pcr
serolog
cumul
incid
subject
protocolspecifi
rsvmari
incid
patientseason
allcaus
mari
common
patientseason
rhinoviru
commonli
identifi
conclus
rsv
infect
common
adult
sever
copd
andor
advanc
chf
given
sever
underli
cardiopulmonari
diseas
studi
popul
ill
surprisingli
mild
thu
activ
immun
rather
passiv
immunoprophylaxi
monoclon
antibodi
may
costeffect
strategi
diseas
control
epidemiolog
immunoprophylaxi
respiratori
syncyti
viru
rsv
season
incid
viru
classif
obstruct
pulmonari
diseas
copd
congest
heart
failur
chf
affect
million
peopl
worldwid
identifi
risk
factor
sever
rsv
infect
addit
patient
may
present
primarili
symptom
decompens
heart
failur
acut
exacerb
copd
aecopd
role
viral
infect
unappreci
although
molecular
diagnost
test
markedli
improv
recognit
rsv
respiratori
virus
set
adult
rsv
remain
underrecogn
problem
effect
mean
prevent
infecti
diseas
vaccin
approach
deploy
protect
largest
atrisk
group
possibl
present
success
rsv
vaccin
remain
elus
passiv
immunoprophylaxi
monoclon
antibodi
palivizumab
highrisk
infant
shown
reduc
rsv
hospit
although
older
adult
increas
risk
sever
rsv
infect
certain
subgroup
sever
copd
chf
may
even
greater
risk
could
potenti
benefit
passiv
immunoprophylaxi
infect
rate
sever
found
substanti
limit
data
avail
incid
rsv
infect
adult
class
iii
iv
copd
andor
chf
observ
studi
design
collect
data
highrisk
popul
adult
exposur
children
might
exhibit
high
rate
infect
sever
ill
infect
rsv
prospect
observ
studi
conduct
across
multipl
consecut
rsv
season
determin
incid
rate
medic
attend
acut
respiratori
ill
mari
event
lead
worsen
cardiorespiratori
statu
adult
sever
copd
andor
advanc
chf
associ
rsv
viral
infect
fiftyseven
site
nine
countri
bulgaria
canada
czech
republ
franc
germani
itali
russia
sweden
unit
state
northern
hemispher
particip
studi
fall
spring
protocol
approv
independ
institut
review
board
subject
sign
written
inform
consent
enrol
studi
popul
includ
adult
year
age
sever
copd
global
initi
chronic
obstruct
lung
diseas
stage
iii
iv
andor
chf
new
york
heart
associ
class
iiiiv
american
colleg
cardiologyamerican
heart
associ
stage
cd
expect
exposur
children
year
age
least
month
acut
respiratori
ill
ari
defin
new
onset
worsen
least
two
follow
respiratori
symptom
sore
throat
nasal
congest
discharg
hoars
cough
sputum
wheez
dyspnea
pleurit
chest
pain
one
respiratori
symptom
system
symptom
feverish
fatigu
headach
myalgia
worsen
cardiorespiratori
event
defin
follow
aecopd
worsen
major
symptom
dyspnea
sputum
volum
sputum
purul
consecut
day
worsen
one
major
symptom
togeth
anyon
minor
symptom
sore
throat
cold
fever
without
caus
increas
cough
wheez
consecut
day
worsen
chf
defin
chang
symptom
sign
pulmonari
edema
dyspnea
weight
gain
pound
pedal
edema
jugular
venou
distens
tachycardia
tachypnea
beyond
normal
daytoday
variat
warrant
medic
chang
mari
consid
ill
subject
sought
outpati
inpati
overthephon
medic
consult
ari
worsen
cardiorespiratori
statu
subject
consid
per
protocol
rsvmari
posit
revers
transcriptas
polymeras
chain
reaction
rtpcr
acut
phase
ill
andor
increas
rsvspecif
serum
antibodi
period
surround
health
care
visit
three
differ
pcr
assay
use
test
rsv
nasal
sputum
sampl
includ
genmark
respiratori
viral
panel
wwwgenmarkdxcom
test
common
respiratori
virus
subtyp
genebas
pcr
assay
assay
detect
rsv
f
n
gene
serolog
rsvspecif
antibodi
measur
enrol
time
mari
acut
approxim
day
ill
convalesc
octob
may
serum
antibodi
measur
use
rsv
neutral
antibodi
assay
rsv
f
ga
gb
nspecif
igg
electrochemiluminesc
ecl
assay
mesoscal
discoveri
platform
rsv
serorespons
defin
rise
neutral
antibodi
titer
rsv
antigen
ecl
assay
season
baselin
sampl
continu
variabl
summar
descript
statist
includ
mean
standard
deviat
median
rang
confid
interv
twosid
unless
otherwis
state
primari
endpoint
object
studi
determin
incid
rate
inpati
outpati
rsvmari
across
multipl
consecut
rsv
season
primari
endpoint
analysi
secondari
outcom
allcaus
mari
death
perform
adjust
individu
subject
followup
time
four
hundr
fiftythre
subject
enrol
studi
invers
relationship
serum
rsv
antibodi
level
incid
rsvmari
observ
figur
higher
antibodi
level
rsv
antigen
associ
lower
incid
rsvmari
relationship
clearli
seen
season
possibl
due
subject
rsvmari
avail
serolog
season
versu
season
vs
respect
season
includ
subject
enrol
throughout
year
preseason
blood
avail
mani
subject
addit
subject
per
protocol
rsvmari
addit
rsv
infect
also
identifi
virus
addit
sputum
test
result
increas
viral
detect
ill
tabl
sever
ill
hospit
prior
studi
howev
popul
adult
class
iiiiv
copd
chf
surpris
ill
sever
expect
previou
studi
highrisk
adult
copd
chf
vari
stage
includ
mild
moder
diseas
rate
rsvmari
personseason
similar
rate
observ
studi
studi
highrisk
patient
hospit
die
infect
rsv
rsv
infect
includ
serolog
diagnos
studi
consid
rsvinfect
subject
hospit
death
notabl
infect
patient
either
asymptomat
mild
ill
requir
medic
intervent
regular
exposur
children
requir
particip
studi
may
led
higher
infect
rate
compar
observ
previou
surveil
vaccin
studi
one
explan
lack
sever
ill
frail
popul
might
regular
exposur
children
result
recent
rsv
infect
studi
lead
increas
protect
baselin
immun
attent
influenza
abrupt
ill
onset
fever
tend
drive
patient
seek
medic
attent
within
sever
day
typic
rsv
ill
begin
cold
progress
sever
day
dyspnea
wheez
averag
time
seek
medic
attent
day
time
viru
may
longer
detect
upper
airway
addit
rsv
infect
adult
repres
reinfect
rapid
amnest
antibodi
respons
may
obscur
rise
antibodi
acut
sera
collect
delay
final
analysi
acut
convalesc
sera
possibl
patient
die
result
may
bias
toward
milder
ill
summari
rsv
well
respiratori
virus
led
signific
morbid
highrisk
person
cardiopulmonari
diseas
find
rsv
result
rel
mild
diseas
patient
advanc
copd
chf
highlight
incomplet
understand
diseas
pathogenesi
adult
given
result
immunoprophylaxi
rsv
monoclon
antibodi
select
highrisk
adult
popul
may
practic
howev
given
overal
burden
rsv
older
adult
program
develop
vaccin
activ
immun
may
feasibl
approach
would
like
thank
studi
particip
site
investig
list
follow
marc
afilalocanada
andreea
